Benchmark-Indikatoren:
Neuer Research-Provider
Im Bereich Research & Ratings können Sie auf Einschätzungen renommierten Analystenhäuser zugreifen, welche sich auf die Due Diligence und Bewertung von in der Regel börsennotierten Unternehmen spezialisiert haben. Ausgehend von den Research-Reports gelangen Sie mit wenigen Mausklicks zu weiteren Recherche-Tools und Informationen, die Ihnen zusätzliche Möglichkeiten zur Informationsgewinnung und Beurteilung der Informationen bieten.
Fr., 26.04.2024
Nynomic AG
High single-digit €m order confirms growth prospects
Nynomic’s subsidiary m-u-t GmbH has received a high single-digit order,
which should translate into sales over the course of FY24/25e. Most
importantly, this coupled with the recently announced product launch of the
LabScanner Plus, a bulk-testing tool for pharmaceutical companies, [ … ]
Fr., 26.04.2024
Nabaltec AG
Final FY23 as expected, solid start into FY24
2023 figures inline with prelims. To recap: FY23 sales decreased by 8.5%
yoy to € 200m, largely driven by the highly cyclical Specialty Alumina
segment, which reported sales of € 57.8m (-18.5% yoy). On the contrary,
Functional Fillers’ sales decreased by only 3.9% to € 142.3m, a [ … ]
Di., 21.11.2023
Cantourage Group SE
Continued strong growth in Q3; chg.
Topic: Cantourage reported preliminary Q3 figures with significant sales
growth and notable EBITDA improvements. The planned abolishment of the
narcotic drug status of medical cannabis in Q1 2024e should further drive
patient numbers and sales growth going forward.
Q3 sales grew by 79% yoy to € 6.1m (9 [ … ]
